Anna-Victoria De Keersmaecker, Eline Van Doninck, Veronica Popescu, Lander Willem, Melissa Cambron, Guy Laureys, Miguel D' Haeseleer, Maria Bjerke, Ella Roelant, Marc Lemmerling, Marie Beatrice D'hooghe, Judith Derdelinckx, Tatjana Reynders, Barbara Willekens
INTRODUCTION: Despite advances in immunomodulatory treatments of multiple sclerosis (MS), patients with non-active progressive multiple sclerosis (PMS) continue to face a significant unmet need. Demyelination, smoldering inflammation and neurodegeneration are important drivers of disability progression that are insufficiently targeted by current treatment approaches. Promising preclinical data support repurposing of metformin for treatment of PMS. The objective of this clinical trial is to evaluate whether metformin, as add-on treatment, is superior to placebo in delaying disease progression in patients with non-active PMS...
2024: Frontiers in Immunology